Drug Discovery

Proteomics
#Drug discovery #Mass spectrometry / NMR #Protein chemistry / Proteomics #Webinar

Webinar: Understand MS-based targeted proteomics

Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. Registrations are now open for a new webinar taking place on 29 January 2026, entitled ‘MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases‘. Read More

Webinar date:
Supported by Evotec
#News

#Artificial intelligence (AI) #Chai Discovery #Drug discovery #Financing

Chai Discovery announces $130m series B financing

Chai Discovery has announced a $130 million Series B financing round co-led by Oak HC/FT and General Catalyst.   The news follows Chai’s most recent announcement, where the company showed its latest models can now design molecules with important “developability” properties and tackle “hard-to-drug” targets that have historically… Read More

#Business & Investment #News

#DDW Turning Science into Business Symposium #Drug discovery #Events

DDW Turning Science into Business Symposium features expert panel: Watch now

Technology, market forces and new ways of working – the challenges facing drug discovery and how to overcome them: This was the topic of the panel discussion at the DDW Turning Science into Business Symposium which took place at the Francis Crick Institute in London on Tuesday 4 November. Read More

#News

#AI #Cell and gene therapy #Charles River #Drug discovery #European Commission #European Union #FDA #Immune cells #Korea #Obesity #Personalised medicine #Rare disease #Regulatory

This week in Drug Discovery (15 – 19 December) 

News round-up for 15 – 19 December by Bruno Quinney, Content Team at DDW.  This week in DDW, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated antibodies have been tolerated by human immune cells.  The top stories:    Scientists discover hidden molecular switch that… Read More

#News

Chemify's Chemifarm
#AI #Chemify #Drug discovery #Tuberculosis

Chemify receives $1.6 million to advance TB drug discovery 

Scottish tech company Chemify has received $1.6 million from the Gates Foundation to continue the discovery of small molecules for tuberculosis (TB).  Building on a successful collaboration with Lgenia, the expanded project will leverage Chemify’s automated platform to design and synthesise new drug leads, aiming to address one of the world’s most… Read More

#Business & Investment #News

#Biobanking #Biospecimen research #Drug discovery #eBook

Foundations of biospecimen success

Advances in biospecimen science are resolving long-standing challenges that have historically hindered research quality, reproducibility, and innovation across drug discovery, translational medicine, and biobanking. These gaps limit scientific progress because even the most sophisticated analytical tools depend on high-quality, well-characterised human biological specimens. This custom eBook from BioIVT explores the… Read More

#eBooks #Resources

Cell and gene therapy concept
#Cell and gene therapy #Charles River #Drug discovery

Charles River to support companies developing therapeutics 

Charles River Laboratories has announced drug discovery companies will receive scientific and commercial expertise as part of the second cohort of its Cell and Gene Therapy Incubator Program (CIP).  The CIP cohort includes six companies, four of which are advanced therapy developers (CureAge Therapeutics, InterAct Therapeutics, Jaan Biotherapeutics and Kopra Bio) and two enabling technology… Read More

#News

#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Precision medicine #Webinar

Webinar: Discover untargeted metabolomics and lipidomics approaches

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar begins with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#News

Artificial intelligence
#AI #Drug discovery #Gene synthesis #Synthetic biology

How AI is transforming gene synthesis and genome engineering 

Ajay Gannerkote, President, Integrated DNA Technologies examines how AI is helping to advance the drug discovery landscape. In the past decade, few fields in biotechnology have evolved as dramatically as gene synthesis and genome engineering.  The evolution of digital technologies, particularly the advent of artificial intelligence (AI), has resulted in… Read More

#Exclusive Content

Synthetic DNA
#Drug development #Genomics #Precision medicine

6-Base sequencing: A tool for better drug development 

Tom Charlesworth, Director of Marketing Strategy and Corporate Development at biomodal examines how 6-base sequencing can unlock advancements in precision medicine.  Call it precision medicine, Genomics 3.0, or the age of multi-omics. However you choose to describe it, the underlying meaning is the same: Our ability to collect and… Read More

#Exclusive Content

#Artificial intelligence (AI) #Drug discovery

From concept to impact: How AI agents and scientific models are accelerating biotech innovation – custom webinar with Benchling Dec 2025

AI has reached a turning point in biotech. Real-world scientific agents are beginning to automate the repetitive tasks that slow down research, and transform how we think about extracting insights from scientific data.    In this webinar, hosted by DDW and supported by Benchling, we will learn how organisations can… Read More

#Webinars

#AI #Drug discovery #Immune cells

AI-generated antibodies tolerated by human immune cells 

AI-generated antibodies have been tolerated by human immune cells, drug discovery company Latent Labs has announced.  The antibody designs, generated by Latent Labs’ AI platform, reportedly displayed drug-like properties, including low ex vivo immunogenicity.   Latent Labs hopes its platform, built on its Latent-X2 model, could significantly shorten… Read More

#News

#AI #Drug discovery #Electronic Lab Notebooks (ELN) #Generative AI #Large language model (LLM)

Why we need to talk about third-generation ELNs 

DDW Editor Reece Armstrong provides a sponsored interview with Rob Brown, PhD, Head of the scientific office at Sapio Sciences.  Electronic lab notebooks (ELNs) have served as essential tools in researchers’ arsenals for decades. But as technology has advanced and the demands of drug discovery and development have… Read More

#Exclusive Content

Microscope
#Biobanking #Biospecimen research #Drug discovery #eBook

eBook: Foundations of biospecimen success

Advances in biospecimen science are resolving long-standing challenges that have historically hindered research quality, reproducibility, and innovation across drug discovery, translational medicine, and biobanking. These gaps limit scientific progress because even the most sophisticated analytical tools depend on high-quality, well-characterised human biological specimens. This custom eBook from BioIVT explores the… Read More

#News

#DDW Turning Science into Business Symposium #Drug discovery #Events

Watch drug discovery experts at DDW Turning Science into Business Symposium

The on-demand version of the DDW Turning Science into Business Symposium is available to watch now!  The event, which took place at The Francis Crick Institute on 4 November, features talks covering aspects of drug discovery including AI, oncology, CRISPR, neuroscience and more.  It… Read More

#News

Novartis head office
#AI #Drug discovery #Novartis

Relation and Novartis to advance atopic disease therapeutics 

UK biopharmaceutical company Relation has partnered with Novartis to advance therapeutics for atopic diseases.  The collaboration will pair Relation’s AI-powered drug discovery platform and human data generation capabilities with Novartis’s expertise in immuno-dermatology to identify, validate, and advance potential first-in-class targets in atopic diseases driven by immune dysregulation.  Under the terms… Read More

#Business & Investment #News